AMIT Technion

Business Overview

Alfred E. Mann established the Alfred Mann Institute for Biomedical Development at Technion-Israel Institute of Technology AMIT is, focused on enabling commercialization of innovative biomedical technologies that improve human health.

Investor type
University
Business model preference
B2B, B2B2C, B2C, B2G
Series preference
Seed, Series A
Offering preference
Software
AI type preference
Artificial Intelligence, Natural Language Processing, Speech Recognition
Sectors
Digital Health Speech Technologies

Investment Portfolio

Startup

Operating Status

Offering Type

Business Model

Total Funding

AI Employees

Voiceitt
Active
Software
B2B, B2B2C, B2C, B2G
$15.8 M
6

Investment Rounds History

Startup

Date Announced

Funding Round

Amount Raised

Investors

August 2020
Series A
$10 M
View All Investors (10 Total)
June 2017
Seed+
$2 M
View All Investors (7 Total)

Similar Investors

TYPE
Venture Capital

INVESTMENTS

5

PORTFOLIO

4

TYPE
Venture Capital
MIN CHEQUE
$0.5 M

INVESTMENTS

25

PORTFOLIO

13

TYPE
Venture Capital
MIN CHEQUE
$0.05 M

INVESTMENTS

1

PORTFOLIO

1

TYPE
Venture Capital

INVESTMENTS

6

PORTFOLIO

3

Sign up for free

  • Save profiles to your list
  • View all funding rounds
  • Advanced sorting filter access
  • Search investment rounds
  • Search exit events